Joint Toxicity Assessment

Joint toxicity assessment evaluates pharmaceutical effects on cartilage, bone, and synovial tissue. Chondrotoxicity from fluoroquinolones increases risk. Bone marrow toxicity compromises haematopoiesis. Synovial fluid penetration predicts cartilage exposure. Age-related susceptibility variation influences risk assessment.

Preclinical joint toxicity models predict human risk. Paediatric populations exhibit heightened susceptibility. Regulatory warnings highlight joint toxicity risks. Clinical monitoring detects early arthralgia patterns. Post-approval surveillance identifies unexpected joint effects.